Log in

Luminex Stock Price, Forecast & Analysis (NASDAQ:LMNX)

-0.10 (-0.50 %)
(As of 11/15/2019 03:20 AM ET)
Today's Range
Now: $19.81
50-Day Range
MA: $20.11
52-Week Range
Now: $19.81
Volume104,200 shs
Average Volume256,172 shs
Market Capitalization$892.48 million
P/E Ratio41.27
Dividend Yield1.81%
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
Current SymbolNASDAQ:LMNX



Sales & Book Value

Annual Sales$315.82 million
Cash Flow$1.04 per share
Book Value$10.21 per share


Net Income$18.51 million


Market Cap$892.48 million
Next Earnings Date2/3/2020 (Estimated)

Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter.

Luminex (NASDAQ:LMNX) Frequently Asked Questions

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex announced a quarterly dividend on Wednesday, July 31st. Shareholders of record on Thursday, September 26th will be given a dividend of $0.09 per share on Thursday, October 17th. This represents a $0.36 annualized dividend and a yield of 1.82%. The ex-dividend date of this dividend is Wednesday, September 25th. This is a boost from Luminex's previous quarterly dividend of $0.06. View Luminex's Dividend History.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) issued its earnings results on Monday, November, 4th. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.09. The medical instruments supplier earned $78.67 million during the quarter, compared to analyst estimates of $81.75 million. Luminex had a negative return on equity of 2.38% and a negative net margin of 2.93%. The firm's revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.04 EPS. View Luminex's Earnings History.

When is Luminex's next earnings date?

Luminex is scheduled to release their next quarterly earnings announcement on Monday, February 3rd 2020. View Earnings Estimates for Luminex.

What price target have analysts set for LMNX?

3 Wall Street analysts have issued twelve-month price targets for Luminex's shares. Their forecasts range from $21.00 to $32.00. On average, they expect Luminex's stock price to reach $26.50 in the next year. This suggests a possible upside of 33.8% from the stock's current price. View Analyst Price Targets for Luminex.

What is the consensus analysts' recommendation for Luminex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

Has Luminex been receiving favorable news coverage?

News coverage about LMNX stock has been trending somewhat negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Luminex earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Luminex.

Are investors shorting Luminex?

Luminex saw a decline in short interest during the month of October. As of October 31st, there was short interest totalling 866,300 shares, a decline of 9.3% from the September 30th total of 954,700 shares. Based on an average trading volume of 180,500 shares, the days-to-cover ratio is currently 4.8 days. Approximately 2.1% of the shares of the stock are sold short. View Luminex's Current Options Chain.

Who are some of Luminex's key competitors?

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), Mondi (MNDI), Alphabet (GOOG), Micron Technology (MU), Nektar Therapeutics (NKTR), Rocket Pharmaceuticals (RCKT), Caterpillar (CAT), Verizon Communications (VZ), Intel (INTC) and Ligand Pharmaceuticals (LGND).

Who are Luminex's key executives?

Luminex's management team includes the folowing people:
  • Mr. Nachum Shamir, CEO, Pres & Director (Age 65)
  • Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 57)
  • Mr. Richard W. Rew II, Sr. VP, Gen. Counsel & Corp. Sec. (Age 51)
  • Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 49)
  • Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 57)

Who are Luminex's major shareholders?

Luminex's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Investment Management of Virginia LLC (2.10%), Hancock Whitney Corp (0.49%), Russell Investments Group Ltd. (0.47%), Great Lakes Advisors LLC (0.41%), Rhumbline Advisers (0.32%) and Fisher Asset Management LLC (0.18%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Nachum Shamir and Todd C Bennett. View Institutional Ownership Trends for Luminex.

Which institutional investors are selling Luminex stock?

LMNX stock was sold by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc., Russell Investments Group Ltd., Hancock Whitney Corp, Fisher Asset Management LLC and Investment Management of Virginia LLC. View Insider Buying and Selling for Luminex.

Which institutional investors are buying Luminex stock?

LMNX stock was purchased by a variety of institutional investors in the last quarter, including Benjamin F. Edwards & Company Inc., Tocqueville Asset Management L.P., Great Lakes Advisors LLC, State of Alaska Department of Revenue, Bridge City Capital LLC, SG Americas Securities LLC, Rhumbline Advisers and California Public Employees Retirement System. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II and Nachum Shamir. View Insider Buying and Selling for Luminex.

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $19.81.

How big of a company is Luminex?

Luminex has a market capitalization of $892.48 million and generates $315.82 million in revenue each year. The medical instruments supplier earns $18.51 million in net income (profit) each year or $0.48 on an earnings per share basis. Luminex employs 988 workers across the globe.View Additional Information About Luminex.

What is Luminex's official website?

The official website for Luminex is http://www.luminexcorp.com/.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]

MarketBeat Community Rating for Luminex (NASDAQ LMNX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  223 (Vote Outperform)
Underperform Votes:  347 (Vote Underperform)
Total Votes:  570
MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote "Outperform" if you believe LMNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Featured Article: Bull Market

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel